The Treatment of Metastatic and Castration-Resistant Prostate Cancer Patients in Korea
10.22465/kjuo.2019.17.1.48
- Author:
Yoon Soo HAH
1
;
U Syn HA
;
Jin Woo JUNG
;
Bong Hee PARK
;
Hyung Joon KIM
;
Ki Hong KIM
;
Jeong Kyun YEO
Author Information
1. Department of Urology, Daegu Catholic University Madical Center, Daegu, Korea.
- Publication Type:Review
- Keywords:
Prostatic neoplasms;
Castration-resistant;
Korea
- MeSH:
Drug Therapy;
Humans;
Korea;
Medical Oncology;
Prostate;
Prostatic Neoplasms;
Quality of Life
- From:Korean Journal of Urological Oncology
2019;17(1):48-59
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
The treatment of advanced prostate cancer has rapidly evolved. Androgen deprivation therapy is recognized as the first-line therapy for metastatic disease; however, a substantial proportion of patients will eventually progress to develop castration-resistance. For the past several years, docetaxel-based chemotherapy has shown significant therapeutic benefit in castration-resistant prostate cancer. Over the last 5 years, several new agents such as the enzalutamide, abiraterone, cabazitaxel, and 223radium have been developed which have all been associated with improved quality of life, pain palliation, and an increase in survival. Unfortunately, there are no Korean treatment guideline for metastatic prostate cancer and/or castration-resistant prostate cancer which has been developed based on adequate review and assessment of evidences. Thus, a guideline adequate for domestic circumstances is eagerly needed. The Korean Association for Clinical Oncology, the Korean Prostate Society, the Korean Urological Oncology Society, and the Korean Society of Pathologists reviewed and endorsed the guidelines.
